Skip to content
ChickenStockChickenStock
ResearchRGNX
Regenxbio logo

Regenxbio (RGNX) stock

NASDAQ

$7.24-1.09%(-0.08)

As of the Nov 17, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-2.73x

Net loss — not comparable

P/B

3.23x

P/S

3.12x

Find stocks with P/B ≤ 0.9×

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue decreased 70.0% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 5, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

11 SEC filings
  • Christmas Patrick J.Chief Strategy & Legal Officer · Nov 1, 2026Grant or award34,722 shares · $0
    Avg. price $0240,690 shares held after
  • Chan MitchellChief Financial Officer · Nov 1, 2026Grant or award24,305 shares · $0
    Avg. price $0147,120 shares held after
  • Malzahn CraigChief Technology Officer · Nov 1, 2026Grant or award27,777 shares · $0
    Avg. price $0109,737 shares held after
  • PAKOLA STEVEChief Medical Officer · Nov 1, 2026Grant or award34,722 shares · $0
    Avg. price $0240,263 shares held after
  • Chan MitchellChief Financial Officer · Sep 1, 2026Shares withheld for taxes4,902 shares · $46K
    Avg. price $9.32122,815 shares held after
  • Malzahn CraigChief Technology Officer · Sep 1, 2026Shares withheld for taxes234 shares · $2K
    Avg. price $9.3281,960 shares held after
  • Ciongoli Gregory AustinDirector · Aug 27, 2026Open-market purchase53,407 shares · $500K
    Avg. price $9.356118,035 shares held after
  • Ciongoli Gregory AustinDirector · Aug 26, 2026Open-market purchase49,196 shares · $450K
    Avg. price $9.141164,628 shares held after
  • Ciongoli Gregory AustinDirector · Aug 25, 2026Grant or award15,432 shares · $0
    Avg. price $015,432 shares held after
  • PAKOLA STEVEChief Medical Officer · Aug 1, 2026Shares withheld for taxes7,468 shares · $72K
    Avg. price $9.69205,541 shares held after
  • Christmas Patrick J.Chief Strategy & Legal Officer · Aug 1, 2026Shares withheld for taxes4,699 shares · $46K
    Avg. price $9.69205,968 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Regenxbio (RGNX) stock information

NASDAQ

Regenxbio (RGNX) is listed on NASDAQ. Its market capitalization is about $478M. On trailing-twelve-month earnings the P/E ratio is -2.73, and the P/B ratio is 3.23. Return on equity is -118.2%. These figures are computed in-house from official filings and are reference information only.

Regenxbio — frequently asked questions

What is the P/E ratio of Regenxbio (RGNX)?
On a trailing-twelve-month basis, RGNX trades at a P/E ratio of -2.73. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Regenxbio?
RGNX has a market capitalization of about $478M. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.